

REMARKS

Claims 25-31, 33-36, 38-40, 42, 43 and 46-48 are pending in this application. Claims 25-29 are withdrawn from consideration, and claims 30, 31, 33-36, 38-40, 42, 43, and 46-48 are rejected. Claims 46-48 are cancelled, and claim 30 is amended herein. Applicants submit that no new matter has been introduced, as support for these amendments can be found in the specification and claims as originally filed.

Rejections under 35 U.S.C. § 112, First Paragraph

Claims 30, 31, and 33-36, 38-40, 42, 43, and 46-48 are rejected under 35 U.S.C. § 112, first paragraph, because “the specification, while being enabling for compounds that inhibit a narrow range of mycobacterium including *tuberculosis*, *bovis*, and *avium intracellulare* ‘*in vitro*,’ does not reasonably provide enablement for the treatment of ‘any’ mycobacterial infection using the full scope of the claimed compounds ‘*in vivo*.’” Office Action at 3. The Examiner further states, “the nature of the invention cannot be fully determined because the invention has not been defined with particularity.” Office Action at 4.

Applicants have amended claim 30 to clarify their invention and claim it with particularity. Specifically, claim 30 as amended is directed to a method for inhibiting growth of a mycobacterial cell, without regard to potential influences of an *in vivo* environment unrelated to growth of the cell. In view of the amended claims, Applicants respectfully submit that the specification and examples enable the claimed invention.

Applicants respectfully submit that the instant claims are enabled under 35 U.S.C. § 112, first paragraph, and this rejection should be withdrawn.

CONCLUSION


An indication of allowance of all claims is respectfully solicited.

Respectfully submitted,

Hunton & Williams, L.L.P.

Dated: October 31, 2007

By: _____


Laurence H. Posorske, PhD.
Registration No. 34,698

Dwight M. Benner II
Registration No. 52,467